REGISTERED NUMBER: 07845520 (England and Wales)

Unaudited Financial Statements

for the Year Ended 31 December 2024

for

PHARMA MODUS LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

Directors:

D Bowden

B L Cantello

Registered office:

18C Caxton Way

Watford

Hertfordshire

WD18 8UA

Registered number:

07845520 (England and Wales)

Accountants:

Cooper Parry Advisory Limited

New Derwent House

69-73 Theobalds Road

London

WC1X 8TA

Fixed assets

Tangible assets

4

22,561

3,299

Current assets

Stocks

372,247

326,071

Debtors

5

842,310

742,282

Cash at bank

87,470

69,081

1,302,027

1,137,434

Creditors

Amounts falling due within one year

6

927,819

702,793

Net current assets

374,208

434,641

Total assets less current liabilities

396,769

437,940

Creditors

Amounts falling due after more than one year

7

6,423

15,967

Net assets

390,346

421,973

Capital and reserves

Called up share capital

8

106

106

Retained earnings

390,240

421,867

Shareholders' funds

390,346

421,973

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 September 2025 and were signed on its behalf by:

B L Cantello - Director

1.	Statutory information

Pharma Modus Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2.	Accounting policies

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

All fixed assets are initially recorded at cost.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:-

Plant & machinery 20% on cost

Website costs 33.33% on cost

Equipment 30% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments

Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument.

Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts.

Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs.

Taxation

Taxation for the year comprises current.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	Employees and directors

The average number of employees during the year was 22 (2023 - 19 ) .

4.	Tangible fixed assets

Plant and

machinery

Website

Equipment

Totals

£

£

£

£

Cost

At 1 January 2024

18,183

3,260

23,458

44,901

Additions

11,380

-

14,028

25,408

At 31 December 2024

29,563

3,260

37,486

70,309

Depreciation

At 1 January 2024

18,153

3,260

20,189

41,602

Charge for year

1,525

-

4,621

6,146

At 31 December 2024

19,678

3,260

24,810

47,748

Net book value

At 31 December 2024

9,885

-

12,676

22,561

At 31 December 2023

30

-

3,269

3,299

5.

Debtors: amounts falling due within one year

2024

2023

£

£

Trade debtors

698,087

568,145

Other debtors

-

170

Directors' current accounts

50,524

73,417

VAT

85,074

92,956

Prepayments and accrued income

8,625

7,594

842,310

742,282

6.

Creditors: amounts falling due within one year

2024

2023

£

£

Bank loans and overdrafts

10,096

10,648

Trade creditors

791,759

579,297

Corporation tax

53,167

44,205

Social security and other taxes

22,276

19,621

Other creditors

31,655

20,238

Directors' current accounts

14,766

14,766

Accruals and deferred income

4,100

14,018

927,819

702,793

7.

Creditors: amounts falling due after more than one year

2024

2023

£

£

Bank loans - 1-2 years

6,423

10,648

Bank loans - 2-5 years

-

5,319

6,423

15,967

8.	Called up share capital

Allotted, issued and fully paid:

Number:

Class:

Nominal

2024

2023

value:

£

£

60

Ordinary A

£1

60

60

40

Ordinary B

£1

40

40

4

Ordinary C

£1

4

4

2

Ordinary D

£1

2

2

106

106

9.	Related party disclosures

At the year end date the company was owed £50,525 by the directors (£73,416 - 2023). This loan was subject to interest at the beneficial rate and repayable on demand.